Amgen Current Deferred Revenue from 2010 to 2026

AMGN Stock  USD 369.20  0.00  0.00%   
Amgen Current Deferred Revenue yearly trend continues to be very stable with very little volatility. Current Deferred Revenue is likely to drop to about -83.2 M. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2010-12-31
Previous Quarter
-79.2 M
Current Value
-83.2 M
Quarterly Volatility
2.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Amgen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amgen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.6 B, Interest Expense of 2.9 B or Selling General Administrative of 2.8 B, as well as many indicators such as Price To Sales Ratio of 8.8, Dividend Yield of 0.0194 or PTB Ratio of 21.36. Amgen financial statements analysis is a perfect complement when working with Amgen Valuation or Volatility modules.
  
Build AI portfolio with Amgen Stock
Check out the analysis of Amgen Correlation against competitors.

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving against Amgen Stock

  0.57VCYT VeracytePairCorr
  0.5CDIOW Cardio DiagnosticsPairCorr
  0.48RAC Race Oncology Earnings Call This WeekPairCorr
  0.46OSE OSE Pharma SAPairCorr
  0.46DXB Dimerix Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Will Biotechnology sector continue expanding? Could Amgen diversify its offerings? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amgen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
1.116
Dividend Share
9.52
Earnings Share
14.21
Revenue Per Share
68.31
Quarterly Revenue Growth
0.086
Investors evaluate Amgen Inc using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Amgen's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Amgen's market price to deviate significantly from intrinsic value.
Understanding that Amgen's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Amgen represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Amgen's market price signifies the transaction level at which participants voluntarily complete trades.